Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 1214 results

Media Release / Sep 01, 2015
Novartis setzt sich weiter für die endgültige Ausrottung von Lepra ein
Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden…
Media Release / Sep 01, 2015
Novartis renouvelle son engagement à l'approche de la dernière ligne droite dans la lutte visant à éradiquer la lèpre
Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau…
Media Release / Sep 01, 2015
Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma
Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…
Media Release / Aug 28, 2015
Novartis continues commitment to go the last mile in effort to eliminate leprosy
New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…
Media Release / Aug 27, 2015
Das Novartis International BioCamp zeigt, wie Zusammenarbeit und Vielfalt Innovationen fördern, und inspiriert künftige wissenschaftliche Führungskräfte
Das International Biotechnology Leadership Camp (BioCamp) fördert das Interesse von Studierenden für wissenschaftlichen Fortschritt und unternehmerische Chancen Anlässlich des interaktiven Programms…
Media Release / Aug 27, 2015
Le Novartis International BioCamp souligne le rôle de la collaboration et de la diversité pour stimuler l'innovation et inspirer les futurs leaders scientifiques.
L'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de…
Media Release / Aug 27, 2015
Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science leaders
The International Biotechnology Leadership Camp (BioCamp) engages students around scientific advances and entrepreneurial opportunities The interactive program brought 70 university students…
Media Release / Aug 24, 2015
FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12…
Media Release / Aug 21, 2015
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a…
Media Release / Aug 20, 2015
Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
Approval follows positive CHMP opinion based on pivotal Phase II study showing durable objective response rate per central review of 56% in patients with laBCC[1] Basal cell carcinoma is…